Cancer Stem Cells: A Review of the Literature and the Implications in Head and Neck Cancer


  • Brianna N. Harris Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine of the University of Southern California, USA
  • Uttam K. Sinha Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine of the University of Southern California, USA



Stem cells, cancer stem cells, head and neck, squamous cell carcinoma, hypoxia inducible factor, curcumin, cisplatin.


 In the last few decades, stem cells have been the focus of researchers in an effort to understand the molecular pathways involved in tissue regeneration. By studying normal cell interactions, researchers have since identified cancer stem cells and demonstrated their role in tumorigenesis and metastasis. The authors aimed to review the major molecular pathways involved in tumorigenesis, the role of cancer stem cells, and emerging therapies that target these pathways in squamous cell carcinoma of the head and neck.


Lukaszewicz AI, McMillan MK, and Kahn M. Small molecules and stem cells. Potency and lineage commitment: the new quest for the fountain of youth. J Med Chem 2010; 53: 3439-53.

Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-7.

Amit M, Carpenter MK, Inokuma MS, et al. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol 2000; 227: 271-8.

Odorico JS, Kaufman DS, Thomson JA. Multilineage differentiation from human embryonic stem cell lines. Stem Cells 2001; 19: 193-204.

Byrne JA. Generation of isogenic pluripotent stem cells. Hum Mol Genet 2008; R37-41.

Warburton D, Perin L, Defilippo R, Bellusci S, Shi W, Driscoll B. Stem/progenitor cells in lung development, injury repair, and regeneration. Proc. Am Thorac Soc 2008; 5: 703-6.

Yacoub M, Suzuki K, Rosenthal N. The future of regenerative therapy in patients with chronic heart failure. Nat Clin Pract Cardivasc Med 2006; 3(Suppl 1): S133-5.

Taupin P. Stroke-induced neurogenesis: physiopathology and mechanisms. Curr Neurovasc Res 2006; 3: 67-72.

Takahaski K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-76.

Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007; I: 39-49.

Yamanaka S. A fresh look at iPS cells. Cell 2009; 137: 13-7.

Li Y, Laterra J. Cancer stem cells: Distinct entities or dynamically regulated phenotypes? Cancer Res 2012; 72: 576-80.

Chambers I, Colby D, Roberston M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003; 113: 643-55.

Hay DC, Sutherland L, Clark J, Burdon T. Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. Stem Cells 2004; 22: 225-35.

Matin MM, Walsh JR, Gokhale PJ, et al. Specific knockdown of Oct4 and beta2-microglobulin expression by RNA interference in human embryonic stem cells and embryonic carcinoma cells. Stem Cells 2004; 22: 659-68.

Mitsui K, Tokuzawa Y, Itoh H, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003; 113: 631-42.

Nichols J, Zevnik B, Anastassiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998; 95: 379-91.

Zaehres H, Lensch MW, Daheron L, Stewart SA, Itskovitz-Eldor J, Daley GQ. High-efficiency RNA interference in human embryonic stem cells. Stem Cells 2005; 23: 299-305.

Lapidot T, SIrard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.

Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.

Zhang M, Rosen JM. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev 2006; 16: 60-4.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.

Cancer Facts and Figures, 2012. American Cancer Society. Obtained from @epidemiologysurveilance/documents/document/acspc-031941.pdf, accessed July 1, 2012.

Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-54.

Vira D, Basak SK, Veena MS, Wang MB, Batra RK, Srivatsan ES. Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metast Rev 2012; 1-20.

Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Natl Acad Sci USA 2007; 104: 973-8.

Davis SJ, Divi V, Owen JH, et al. Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2010; 136: 1260-6.

Takahashi E, Nagano O, Ishimoto T, et al. Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem 2010; 285: 4060-73.

Oh SY, Kang HJ, Kim YS, Kim H, Lim YC. CD44-negative cells in head and neck squamous cell carcinoma have stem-cell like traits. Eur J Cancer 2012; 1-9.

Bhaijee F, Pepper DJ, Pitman KT, Bell D. Cancer stem cells in head and neck squamous cell carcinoma: A review of current knowledge and future applications. Basic Sci Rev 2012; 894-9.

Visus C, Ito D, Amoscato A, et al. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8þ T- cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res 2007; 67: 10538-45.

Zhang P, Zhang Y, Mao L, Zhang Z, Chen W. Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Lett 2009; 277: 227-34.

Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD. A subpopulation of CD133+ cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 2010; 289L: 151-60.

Chen H, Zhou L, Dou T, Wan G, Tang H, Tian J. BMI1’s maintenance of the proliferative capacity of laryngeal cancer stem cells. Head & Neck 2011; 33: 1115-25.

Clay MR, Tabor M, Owen J, et al. Single-marker identification of head anc neck squamous cell cancer stem cells with aldehyde dehydrogenase. Head & Neck 2010; 32: 1195-201.

Albers AE, Chen C, Koberle B, et al. Stem cells in squamous head and neck cancer. Crit Rev Oncol/Hematol 2012; 81: 224-40.

Sun S, Wang Z. Head neck squamous cell carcinoma c-Met(+) cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer 2011; 129: 2337-48.

Tabor MH, Clay MR, Owen JH, et al. Head and neck cancer stem cells: the side population. Laryngoscope 2011; 121: 527-33.

Song J, Chang I, Chen Z, Kang M, Wang CY. Characterization of side populations in HNSCC: highly invasive, chemo resistant and abnormal Wnt signaling. PLoS One 201; 5: e11456.

Mannelli G, Gallo O. Cancer stem cells hypothesis and stem cells in head and neck cancers. Cancer Treatment Reviews 2012; 38: 515-39.

Lin Q, Yun Z. Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics. Cancer Biol Ther 2012: 9: 949-56.

Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102: 789-95.

Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glimoa stem cells. Cancer Cell 2009; 15: 501-13.

Griguer CE, Oliva CR, Gobin E, et al. CD133 is a marker of bioenergetics stress in human glioma. PloS One 2008; 3: 3655.

Soeda A, Park M, Lee D, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28: 949-59.

Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.

Wend P, Holland JD, Ziebold U, Birchmeier W. Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol 2010; 21: 855-63.

Kypta R, Waxman J. Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol 2012; 1-11.

Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-80.

Hoffmeyer K, Raggiloi A, Rudloff S, et al. Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells. Science 2012; 336: 1549-54.

Yao H, Ashihara E, Maekawa T. Targeting the Wnt/β-catenin signaling pathway in human cancers. Informa 2011; 15: 873-87.

Hu FW, Tsai LL, Yu CH, Chen PN, Chou MY, Yu CC. Impairment of tumor-initiating stem-lie property and reversal of epithelial-mesenchymal transdifferentiation in head and neck cancer by resveratrol treatment. Mol Nutr Food Res 2012; 1-12.

Chen C, Zimmermann M, Tinhofer I, Kaufmann A, Albers A. Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma. Cancer Lett 2012; 1-10.

Zhang Z, Filho MSA, Nor JE. The biology of head and neck cancer stem cells. Oral Oncol 2012; 48: 1-9.

Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Semin Cancer Biol 2012; 22: 396-403.

Brabletz T, Jung A, Spaderna S, et al. Opinion: migrating cancer stem cells. An integrated concept of malignant tumor progression. Nat Rev Cancer 2005; 5: 744-9.

Geng S, Guo Y, Wang Q, Li L, Wang J. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma. Arch Dermatol Res 2012.

Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.

Mimeault M, Batra SK. Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med 2008; 50: 3-18.

Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994; 269: 787-90.

Yilmaz T, Jiffar T, de la Garza G, et al. Theraputic targeting of Trk suppresses tumor proliferation and enhances cisplatin activity in HNSCC. Cancer Biol Ther 2010; 10: 644-53.

Saha S, Adhikary A, Bhattacharyya P, Das T, Sa G. Death by design: where curcumin sensitizes drug-resistant tumours. Anticancer Res 2012; 32: 2567-84.

Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nonparticles inhibit ovarian cancer cell growth. J Ovarian Res 2010; 3: 11.

Abuzeid WM, Davis S, Tang AL, et al. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog. Arch Otolaryngol Head Neck Surg 2011; 137: 499-507.

Wu AW, Basak SK, Lai C, Veena MS, Wang MB, Srivatsan ES. CD44 High head and neck cancer cells demonstrate increased cell growth and chemotherapeutic resistance. AACR 101st Annual Meeting 2010, Washington DC, 12-21 April 2010.

Lim YC, Kang HJ, Kim YS, Choi EC. All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/β-catenin pathway. Eur J Cancer 2012; 2-9.

Masood R, Roy I, Zu S, et al. Gold nanorod-sphingosine kinase siRNA nanocomplexes: a novel therapeutic tool for potent radiosensitization of head and neck cancer. Integr Biol 2012; 4: 132-41.




How to Cite

Brianna N. Harris, & Uttam K. Sinha. (2013). Cancer Stem Cells: A Review of the Literature and the Implications in Head and Neck Cancer . Journal of Cancer Research Updates, 2(3), 186–193.